(3-Bromo-5-methyl-phenyl)methanol (12): This compound was synthesized according to GP-A, using 3-bromo-5-methylbenzaldehyde (10, 2.20 g, 11.0 mmol), MeOH (35 mL) and NaBH4 (0.208 g, 5.50 mmol). The crude was purified by flash column chromatography (pentane/Et2O 4:1), to afford 12 as a white solid (2.01 g, 10.0 mmol, 91%). M.p. 46-48 °C. 1 H-NMR (400 MHz, CDCl3) δ 7.30 (s, 1H), 7.25 (s, 1H), 7.08 (s, 1H), 4.61 (s, 2H), 2.32 (s, 3H), 1.92 (s, 1H). 13 C-NMR (101 MHz, CDCl3) δ 142.9 (C), 140.5 (C), 131.3 (CH), 127.0 (CH), 126.3 (CH), 122.5 (C), 64.6 (CH2), 21.2 (CH3). IR (cm -1 ) 3306, 2914 , 2865 , 1605 , 1573 , 1443 , 1253 , 1024 
3-(Hydroxymethyl)-5-(methyl)benzaldehyde (14):
This compound was synthesized according to GP-B, using 12 (1.0 g, 4.97 mmol), anhydrous THF (40 mL), i PrMgCl (2.0 M in THF, 2.74 mL, 5.47 mmol), n BuLi (2.5 M in hexanes, 4.37 mL, 10.93 mmol) and anhydrous DMF (7 mL, 90.8 mmol). The crude was purified by flash column chromatography (pentane/Et2O 1:1), to afford 14 as a yellow oil (0.487 g, 3.24 mmol, 65%). 1 H-NMR (400 MHz, CDCl3) δ 9.99 (s, 1H), 7.68 (s, 1H), 7.62 (s, 1H), 7.47 (s, 1H), 4.76 (s, 2H), 2.44 (s, 3H), 1.74 (br s, 1H). 13 C-NMR (101 MHz, CDCl3) δ 192.7 (CHO), 142.0 (C), 139.4 (C), 136.8 (C), 133.8 (CH), 129.5 (CH), 125.5 (CH), 64.6 (CH2), 21.3 (CH3). IR (cm -1 ) 3379, 2921, 2869, 2734, 1690, 1599, 1294, 1142, 1039, 856, 682, 631 
2-(3-(Hydroxymethyl)-5-methylbenzyl)-3-(phenylamino)acrylonitrile (16):
This compound was synthesized according to GP-C, using 14 (0.450 g, 2.99 mmol), 3-anilinopropionitrile (0.524 g, 3.59 mmol), anhydrous DMSO (4.2 mL) and NaOMe (2.0 M in MeOH, 1.79 mL, 3.59 mmol). The crude was purified by flash column chromatography (CH2Cl2/MeOH 99:1), to afford 16 as a pale yellow solid (0.230 g, 0.826 mmol, 28%). 1 H-NMR (400 MHz, CD3OD) δ 7.53 (s, 1H), 7.30-7.26 (m, 2H), 7.11-7.08 (m, 3H), 7.06-7.02 (m, 2H), 6.99-6.95 (m, 1H), 4.56 (s, 2H) , 3.59 (s, 2H), 2.33 (s, 3H). 13 C-NMR (101 MHz, CD3OD) δ 143.0 (C), 142.9 (C), 142.5 (CH), 139.7 (C), 139.4 (C), 130.6 (2 CH), 129.1 (CH), 127.1 (CH), 125.2 (CH), 124.1 (CN), 123.3 (CH), 116.5 (2 CH), 83.4 (C), 65.2 (CH2), 32.8 (CH2), 21.4 (CH3). IR (cm -1 ) 3020, 2913, 2865, 2473, 2445, 2189, 1630, 1597, 1501, 1347, 1240, 748, 685, 504 3336, 3154, 3069, 3024, 2788, 2674, 1661, 1594, 1569, 1464, 1434, 1065, 835, 774, 604, 519 (3-Bromo-5-(trifluoromethyl)phenyl)methanol (13): This compound was synthesized according to GP-A, using 3-bromo-5-(trifluoromethyl)benzaldehyde (11, 0.50 g, 1.98 mmol), MeOH (8.0 mL) and NaBH4 (0.038 g, 0.99 mmol). The crude was purified by flash column chromatography (pentane/Et2O 9:1 to 8:2), to afford 13 as a white solid (0.438 g, 1.72 mmol, 87%). M.p. 50-51 °C. 1 H-NMR (400 MHz, CDCl3) δ 7.71 (s, 1H), 7.68 (s, 1H), 7.56 (s, 1H), 4.75 (s, 2H), 1.80 (br s, 1H) 13 C-NMR (101 MHz, CDCl3) δ 144.1 (C), 133.1 (q, J = 1.0, CH), 132.7 (q, J = 33.0, C), 127.6 (q, J = 3.8, CH), 123.3 (q, J = 272.9, CF3) 123.0 (C), 122.2 (q, J = 3.8, CH), 63.9 (CH2). 19 F-NMR (376 MHz, CDCl3) δ -62.86. IR (cm -1 ) 3244, 3099, 2932, 2873, 1443, 1315, 1157, 1121, 1097, 1048, 865, 793, 693 . HRMS (ESI-) calculated for C8H5BrF3O [M -H] -252.9470, found 252.9482.
3-(Hydroxymethyl)-5-(trifluoromethyl)benzaldehyde (15):
This compound was synthesized according to GP-B, using 13 (0.418 g, 1.64 mmol), anhydrous THF (13 mL), i PrMgCl (2.0 M in THF, 0.90 mL, 1.80 mmol), n BuLi (2.5 M in hexanes, 1.44 mL, 3.60 mmol) and anhydrous DMF (2.3 mL, 29.8 mmol). The crude was purified by flash column chromatography (pentane/Et2O 4:1), to afford 15 as a colorless oil (0.221 g, 1.08 mmol, 66%). 3358, 2962, 2204, 1651, 1591, 1275, 1218, 1145, 1121, 1106, 1030, 756 
Synthesis of deazathiamine derivatives 19-24

5-((5-((Benzyloxy)methyl)-4-methylthiophen-3-yl)methyl)-2-methyl-pyrimidin-4-amine (19):
To a solution of NaH (previously washed twice with pentane to remove the oil, in a Schlenk flask under N2; 14.4 mg, 0.600 mmol) in anhydrous DMF (0.20 mL), 2 (50.0 mg, 0.200 mmol) was added. The reaction mixture was stirred at room temperature for 1 h. Then, benzyl bromide (34.3 mg, 0.200 mmol) and anhydrous DMF (0.2 mL) were added (slow addition of benzyl bromide, exothermic!), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched with a saturated aqueous solution of NH4Cl, extracted 3 times with CH2Cl2, and the combined organic layers were washed once with water, once with a saturated aqueous solution of NaCl, dried over MgSO4, filtered and concentrated under reduced pressure. 3277, 3223, 3095, 2922, 2856, 1670, 1597, 1557, 1482, 1427, 1650, 1080, 739, 702, 599 . HRMS (ESI+) calculated for C19H22N3OS [M + H] + 340.1478, found 340.1476. Two side products were isolated: N-benzylated (4.60 mg, 0.0135 mmol) and dibenzylated (7.0 mg, 0.016 mmol) compounds. Amino-2-methylpyrimidin-5-yl)methyl)-3-methylthiophen-2-yl)ethyl 1H-indole-3-carboxylate (20) : To a solution of 26 (25.0 mg, 59.9 μmol) in CH3CN (0.5 mL), DBU (18.2 mg, 0.119 mmol) was added. Then, a solution of indole-3-carboxylic acid (19.3 mg, 0.119 mmol) in CH3CN (0.2 mL), and tetrabutylammonium iodide (5.40 mg, 1.46 μmol) were added, and the reaction mixture was stirred at room temperature for 3 days. Subsequently, water and CH2Cl2 were added to the reaction mixture, and the phases were separated. The aqueous layer was extracted 3 times with CH2Cl2, and the four combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure. After a flash column chromatography (CH2Cl2/MeOH 97:3), the product was mixed with tetrabutylammonium iodide, and it was purified by HPLC (Shimadzu HPLC-PDA, Column XTerra ® Prep MS C18 10 μm 7.8x150 mm; method: 15 min, gradient from H2O (0.1% TFA)/CH3CN (0.1% TFA) 95:5 to 5:95, then hold for 3 min at H2O (0.1% TFA)/CH3CN (0.1% TFA) 5:95; flow rate 1 mL min -1 ) to afford 20 as a white solid (1.85 mg, 4.55 μmol, 6%). 1 H-NMR (400 MHz, CD3OD) δ 8.02-7.99 (m, 1H), 7.96 (s, 1H), 7.45-7.43 (m, 2H), 7.23-7.13 (m, 2H), 6.94 (s, 1H), 4.49 (t, J = 6.6, 2H), 3.70 (s, 2H), 3.27 (t, J = 6.6, 2H), 2.53 (s, 3H), 2.11 (s, 3H). 
2-(4-((4-
General procedure for the reductive amination in the synthesis of 21, 22 and 23 (GP-E).
To a solution of aldehyde 25 (1.0 eq) in anhydrous DMF, the corresponding amine (1.2 eq), MeOH and MgSO4 (added when the reaction mixture is homogenous) were added. The reaction mixture was stirred at 60 °C (pre-heated oil bath) for 20 h. Then, the reaction mixture was cooled down, NaBH4 (0.5-1.0 eq) was added, and the reaction mixture was stirred at room temperature for 20 h. Subsequently, the solution was filtered, and the solvent was evaporated under reduced pressure. The crude was purified by flash column chromatography.
5-((5-(((2,2-Diphenylethyl)amino)methyl)-4-methylthiophen-3-yl)methyl)-2-methylpyrimidin-4-amine (21):
This compound was synthesized according to GP-E, using aldehyde 25 (80.0 mg, 0.324 mmol), anhydrous DMF (1.8 mL), 2,2-diphenylethylamine (76.5 mg, 0.388 mmol), MeOH (ca. 0.1 mL), MgSO4 (ca. 50 mg), and later NaBH4 (12.3 mg, 0.324 mmol). The crude was purified by flash column chromatography (CH2Cl2/MeOH 95:5), to afford 21 as a white solid (84.8 mg, 0.198 mmol, 61%) . M.p. 54-56 ºC. 1 H-NMR (400 MHz, CD3OD) δ 7.58 (s, 1H), 7.29-7.14 (m, 10H), 6.84 (s, 1H), 4.17 (t, J = 7.8, 1H), 3.88 (s, 2H), 3.61 (s, 2H), 3.23 (d, J = 7.8, 2H), 2.40 (s, 3H), 1.92 (s, 3H). 13 C-NMR (101 MHz, CD3OD) δ 166.3 (C), 163.6 (C), 154.5 (CH), 144.0 (2 C), 138.7 (C), 137.9 (C), 134.9 (C), 129.7 (4 CH), 129.0 (4 CH), 127.7 (2 CH), 121.3 (CH), 114.0 (C), 54.0 (CH2), 52.1 (CH), 46.6 (CH2), 28.7 (CH2), 24.8 (CH3), 12.2 (CH3). IR (cm -1 ) 3321, 3147, 2919, 2833, 1629, 1590, 1558, 1449, 1116, 970, 740, 698 . HRMS (ESI+) calculated for C26H29N4S [M + H] + 429.2107, found 429.2100. Adamantan-1-yl) methyl)amino)methyl)-4-methylthiophen-3-yl)methyl)-2-methylpyrimidin-4-amine (22): This compound was synthesized according to GP-E, using aldehyde 25 (45.0 mg, 0.18 mmol), anhydrous DMF (1 mL), 1-adamantane-methylamine (39 μL, 0.22 mmol), MeOH (ca. 0.1 mL), MgSO4 (ca. 20 mg), and later NaBH4 (3.4 mg, 0.09 mmol) The crude was purified by flash column chromatography (CH2Cl2/MeOH 95:5), to afford 22 as a yellow solid (0.023 g, 0.058 mmol, 32%). M.p. 74-76 °C. 1 H-NMR (400 MHz, CD3OD) δ 7.57 (s, 1H), 6.88 (s, 1H), 3.89 (s, 2H), 3.65 (s, 2H), 2.39 (s, 3H), 2.27 (s, 2H), 2.06 (s, 3H), 1.98-1.92 (m, 3H), 1.78-1.65 (m, 6H), 1.56-1.52 (m, 6H). 13 C-NMR (101 MHz, CD3OD) δ 166.2 (C), 163.7 (C), 154.4 (CH), 139.4 (C), 138.5 (C), 134.4 (C), 121.1 (CH), 114.2 (C), 62.6 (CH2), 48.0 (CH2), 41.9 (3 CH2), 38.2 (3 CH2), 34.4 (C), 29.9 (3 CH), 28.7 (CH2), 24.7 (CH3), 12.3 (CH3). IR (cm -1 ) 3322, 3168, 2898, 2845, 1635, 1592, 1560, 1435, 1237, 1107, 1034, 973, 734 . HRMS (ESI+) calculated for C23H33N4S [M + H] + 397.2420, found 397.2418. -2-ylmethyl) amino)methyl)-thiophen-3-yl)methyl)pyrimidin-4-amine (23): This compound was synthesized according to GP-E, using aldehyde 25 (16.0 mg, 0.065 mmol), DMF (0.3 mL), 2-(aminomethyl)pyridine (8.0 μL, 0.078 mmol), MeOH (ca. 0.05 mL), MgSO4 (ca. 10 mg), and later NaBH4 (13.0 mg, 
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